Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Merck & Co., Inc.

Clinical Interchange: Bladder Cancer Treatment in an Era of Novel Mechanistic Approaches: Emerging Clinical Considerations

Release Date: May 15, 2020
Expiration Date: May 15, 2021

Activity Overview

This online educational activity consists of a series of videos from a previously live webcast designed to present new clinical data and its implications for the treatment of urothelial carcinoma. Case scenarios and panel discussions engage a panel of genitourinary specialists in conversations about immunotherapy and targeted therapy approaches to bladder cancer care. Topics include treatment of early-stage and advanced bladder cancer, managing relapsed or refractory disease, and current and future strategies for muscle-invasive and non–muscle-invasive bladder cancer.

Acknowledgement of Support

This activity is supported by an educational grant from Merck & Co., Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward oncologists, urologists, and investigators interested in the treatment of bladder cancers. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with bladder cancers will be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Describe the mechanistic rationale for using targeted and immunotherapeutic approaches to treat bladder cancer.
  • Integrate results from pivotal clinical trials evaluating novel strategies for the treatment of bladder cancer, including immunotherapeutics, targeted agents, and emerging biomarker data, to develop personalized treatment plans for individual patients.
  • Discuss novel agents and combinatorial approaches under investigation for the treatment of bladder cancer across multiple settings, including advanced, metastatic, muscle-invasive, and non–muscle-invasive disease.
  • Consider practice-changing evidence in the context of multidisciplinary, team-based care planning for patients with bladder cancer.
  • Discuss strategies to monitor, identify, and mitigate the impact of treatment-related toxicities that may occur among patients receiving treatment for bladder cancer.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Arjun V. Balar, MD
Arjun V. Balar, MD
Associate Professor of Medicine
Director – Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, NY

Disclosures: Fees for Consultant/Advisory Role: Incyte Corporation, Janssen Pharmaceuticals Inc, Pfizer Inc; Fees for Contracted Research (institution), Consultant/Advisory Role, Speaking Engagements: Genentech Inc; Fees for Contracted Research (institution), Consultant/Advisory Role, Speaking Engagements, Steering/Scientific Advisory Committee: Merck & Co Inc; Fees for Consultant/Advisory Role, Contracted Research (institution), Speaking Engagements: AstraZeneca/MedImmune LLC; Fees for Consultant Advisory Role, Contracted Research, Steering Committee Membership: Nektar Therapeutics; Fees for Consultant/Advisory Role, Contracted Research (institution): Seattle Genetics Inc; Fees for contracted research (institution): Immunomedics Inc.

Leonard G. Gomella, MD, FACS
Leonard G. Gomella, MD, FACS
The Bernard W. Godwin Professor of Prostate Cancer
Chairman, Department of Urology
Senior Director Clinical Affairs, Sidney Kimmel Cancer Center
Clinical Director, Jefferson Kimmel Cancer Center Network
Thomas Jefferson University
Philadelphia, PA

Disclosures: Consultant: Astellas Pharma Inc, Bayer AG, Merck & Co Inc, Strand Therapeutics; Other: NCI-NRG.

Elizabeth Plimack, MD, MS
Elizabeth Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Philadelphia, PA

Disclosures: Grant Research Support: Astellas Pharma Inc, Bristol Myers Squibb, Genentech Inc, Merck & Co Inc; Consultant: Bristol Myers Squibb, Flatiron Health, Genentech Inc, Janssen Pharmaceuticals Inc, Merck & Co Inc, Seattle Genetics, AstraZeneca, Pfizer Inc; Other: CME honoraria recipient: American Urological Association, Clinical Care Options LLC, Fox Chase Cancer Center, Georgetown University, Medscape, National Comprehensive Cancer Network, Physicians’ Education Resource LLC, prIME Oncology, Research to Practice.

Gary D. Steinberg, MD
Gary D. Steinberg, MD
Professor, Department of Urology
Director, Urology Bladder Cancer Program
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, NY

Disclosures: Scientific Advisor/Consultant: Heat Biologics Inc, CG Oncology Inc, PhotoCure ASA, Merck & Co Inc, Roche/Genentech Inc, Ciclomed LLC, Taris Biomedical, MDxHealth, Fidia Farmaceuticals USA Inc, UroGen, Ferring Pharmaceuticals, Aduro Inc, Boston Scientific, Bristol Myers Squibb, AstraZeneca, Pfizer Inc, Janssen Pharmaceuticals Inc, EpiVax Oncology, Natera Inc, FKD Therapies, Ferring Pharmaceuticals Inc, EnGene Inc, SesenBio Inc, Anchiano Therapeutics, Nucleix Ltd, Ipsen Pharma, Combat Medical Systems LLC, Astellas Pharma Inc, Fergene Inc; Equity/Stock Options: EpiVax Oncology, UroGen Pharma; Other: member of Clinical Trial Protocol Committees for the following companies: Merck & Co Inc, Bristol Myers Squibb, Janssen Pharmaceuticals Inc, CG Oncology Inc, Pfizer Inc, PhotoCure, Fidia Farmaceuticals USA Inc.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By